[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20010196L - Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft - Google Patents

Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft

Info

Publication number
NO20010196L
NO20010196L NO20010196A NO20010196A NO20010196L NO 20010196 L NO20010196 L NO 20010196L NO 20010196 A NO20010196 A NO 20010196A NO 20010196 A NO20010196 A NO 20010196A NO 20010196 L NO20010196 L NO 20010196L
Authority
NO
Norway
Prior art keywords
diagnosis
therapy
compositions
methods
prostate cancer
Prior art date
Application number
NO20010196A
Other languages
English (en)
Other versions
NO20010196D0 (no
Inventor
Davin Clifford Dillon
Susan Louise Harlocker
Jiang Yuqiu
Jiangchun Xu
Jennifer Lynn Mitcham
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/115,453 external-priority patent/US6657056B2/en
Priority claimed from US09/116,134 external-priority patent/US7008772B1/en
Priority claimed from US09/159,812 external-priority patent/US6613872B1/en
Priority claimed from US09/232,149 external-priority patent/US6465611B1/en
Priority claimed from US09/232,880 external-priority patent/US7270980B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20010196D0 publication Critical patent/NO20010196D0/no
Publication of NO20010196L publication Critical patent/NO20010196L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20010196A 1998-07-14 2001-01-12 Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft NO20010196L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/115,453 US6657056B2 (en) 1997-02-25 1998-07-14 Compounds for immunotherapy of prostate cancer and methods for their use
US09/116,134 US7008772B1 (en) 1997-02-25 1998-07-14 Compounds for immunodiagnosis of prostate cancer and methods for their use
US15982298A 1998-09-23 1998-09-23
US09/159,812 US6613872B1 (en) 1997-02-25 1998-09-23 Compounds for immunotherapy of prostate cancer and methods for their use
US09/232,149 US6465611B1 (en) 1997-02-25 1999-01-15 Compounds for immunotherapy of prostate cancer and methods for their use
US09/232,880 US7270980B2 (en) 1997-02-25 1999-01-15 Compounds for immunodiagnosis of prostate cancer and methods for their use
US28894699A 1999-04-09 1999-04-09
PCT/US1999/015838 WO2000004149A2 (en) 1998-07-14 1999-07-14 Compositions and methods for therapy and diagnosis of prostate cancer

Publications (2)

Publication Number Publication Date
NO20010196D0 NO20010196D0 (no) 2001-01-12
NO20010196L true NO20010196L (no) 2001-03-12

Family

ID=27568734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010196A NO20010196L (no) 1998-07-14 2001-01-12 Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft

Country Status (17)

Country Link
EP (2) EP1097208A2 (no)
JP (1) JP2002520054A (no)
KR (2) KR20010083111A (no)
CN (1) CN100419079C (no)
AU (2) AU762812B2 (no)
BR (1) BR9912007A (no)
CA (1) CA2334038A1 (no)
CZ (1) CZ2001149A3 (no)
HU (1) HUP0203035A3 (no)
IL (1) IL140845A0 (no)
NO (1) NO20010196L (no)
NZ (1) NZ509178A (no)
PL (1) PL200772B1 (no)
SA (1) SA99200618B1 (no)
TR (1) TR200100916T2 (no)
TW (2) TW200532020A (no)
WO (1) WO2000004149A2 (no)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828431B1 (en) * 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
EP1007650B1 (en) 1997-04-10 2009-03-18 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, pca3 genes, and methods of use
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE69941187D1 (de) 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP1117794A2 (en) * 1998-10-02 2001-07-25 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CN1352683A (zh) * 1999-04-09 2002-06-05 科里克萨有限公司 用于治疗和诊断乳腺癌的组合物和方法
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
WO2001004143A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Biologicals S.A. Prostase vaccine
CA2385477C (en) 1999-09-29 2009-11-03 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
AU7917200A (en) 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
CA2385032C (en) * 1999-10-05 2013-12-10 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
WO2001025446A1 (en) * 1999-10-07 2001-04-12 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
JP2004537252A (ja) * 1999-11-12 2004-12-16 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
PL356908A1 (en) * 2000-01-14 2004-07-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001059110A2 (en) * 2000-02-08 2001-08-16 Agensys, Inc. 34p3d7: a tissue specific protein highly expressed in prostate cancer
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US20030165831A1 (en) * 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1311673A2 (en) * 2000-03-27 2003-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
GB0015736D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Biolog Vaccine
DK2266603T3 (da) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1343912A2 (en) 2000-11-28 2003-09-17 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
MXPA03004688A (es) 2000-11-28 2003-09-05 Wyeth Corp Analisis de expresion de acidos nucleicos y polipeptidos fkbp utiles en diagnostico.
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
CA2446788A1 (en) * 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
CA2459318C (en) 2001-09-06 2017-09-26 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002258689C1 (en) * 2002-04-01 2008-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
DE60313163T2 (de) * 2002-06-11 2008-01-03 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzungen
AU2003250828A1 (en) * 2002-06-11 2003-12-22 Glaxo Group Limited Immunogenic compositions comprising a xenogenic prostate protein p501s
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
ES2427853T3 (es) 2003-02-07 2013-11-04 Diagnocure Inc. Procedimiento para detectar cáncer de próstata en una muestra
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
ES2443996T3 (es) 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
DE06814528T1 (de) 2005-09-12 2012-01-05 The Regent Of The University Of Michigan Wiederkehrende genfusionen bei prostatakrebs
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008016111A1 (en) 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Method for evaluation of lung cancer, lung cancer evaluation apparatus, lung cancer evaluation method, lung cancer evaluation system, lung cancer evaluation program, and recording medium
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
WO2008075663A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体
JP5746810B2 (ja) 2006-12-21 2015-07-08 味の素株式会社 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
EP2171094B1 (en) 2007-07-06 2011-11-16 The Regents of the University of Michigan Mipol1-etv1 gene rearrangements
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
KR100976218B1 (ko) 2008-05-26 2010-08-17 한국표준과학연구원 비행시간이차이온질량분광법을 이용한 질병의 진단 방법,질병 지표의 스크린 방법, 및 질병 지표
WO2009154297A1 (ja) * 2008-06-20 2009-12-23 味の素株式会社 前立腺疾患の評価方法
WO2010016527A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
CN102112146B (zh) * 2008-08-05 2014-03-12 东丽株式会社 免疫诱导剂
US8778621B2 (en) * 2009-05-12 2014-07-15 Koninklijke Philips N.V. Phosphodiesterase 4D7 as marker for malignant, hormone-sensitive prostate cancer
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
JP5800817B2 (ja) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
BR112012018948B1 (pt) 2010-02-04 2021-12-14 Toray Industries, Inc Composições farmacêuticas, anticorpos, combinação farmacêutica, usos de uma composição farmacêutica, uso de um anticorpo e uso de uma combinação farmacêutica
DK2532367T3 (en) 2010-02-04 2018-11-19 Toray Industries PHARMACEUTICAL AGENT FOR TREATMENT AND / OR CANCER PREVENTION
US8828398B2 (en) 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EA201391183A1 (ru) 2011-02-15 2014-02-28 Иммьюн Дизайн Корп. Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN103717238B (zh) 2011-08-04 2016-10-12 东丽株式会社 胰癌的治疗和/或预防用药物组合物
AU2012290955B2 (en) 2011-08-04 2017-04-27 Toray Industries, Inc. Drug composition for cancer treatment and/or prevention
PL2741085T3 (pl) 2011-08-04 2017-09-29 Toray Industries, Inc. Sposób wykrywania raka trzustki
DK2740794T3 (en) 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE033183T2 (en) 2011-08-04 2017-11-28 Toray Industries A medicament for treating and / or preventing cancer
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
DK2818481T3 (da) 2012-02-21 2019-10-14 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
RU2632645C2 (ru) 2012-02-21 2017-10-06 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
DK2818483T3 (en) 2012-02-21 2017-10-23 Toray Industries Medical composition for the treatment and / or prevention of cancer
CA2865020C (en) 2012-02-21 2021-01-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
WO2013147169A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
JP6463672B2 (ja) * 2012-05-25 2019-02-06 セレクティスＣｅｌｌｅｃｔｉｓ Ｔｃｒアルファ欠損ｔ細胞を増殖させるためのプレｔアルファまたはその機能性変種の使用
US9753038B2 (en) 2012-07-19 2017-09-05 Toray Industries, Inc. Method for detecting cancer via measurement of caprin-1 expression level
US9772332B2 (en) 2012-07-19 2017-09-26 Toray Industries, Inc. Method for detecting CAPRIN-1 in a biological sample
BR112015004349B1 (pt) 2012-09-11 2022-11-01 Oncotherapy Science, Inc Composição e método in vitro para indução de um ctl, composição farmacêutica para o tratamento de câncer, método in vitro para indução de uma apc com capacidade de indução de ctl, bem como uso e método para avaliação de um peptídeo que apresenta uma habilidade para induzir um ctl
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
IL310015A (en) 2013-12-31 2024-03-01 Access To Advanced Health Inst Single vial vaccine formulations
WO2016011083A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
JOP20200228A1 (ar) * 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
CN108472350A (zh) * 2016-01-08 2018-08-31 瓦西博迪公司 新表位rna癌症疫苗
EP3443123B1 (en) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
CA3023271A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
JP2022512921A (ja) * 2018-11-07 2022-02-07 アコーオス インコーポレイテッド 有毛細胞の分化を誘導する組成物及び方法
CN111000858B (zh) * 2019-05-10 2021-04-09 常州市第二人民医院 Nupr1抑制剂在制备膀胱癌治疗药物中的用途
EP3976092A1 (en) 2019-05-25 2022-04-06 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CN111968751B (zh) * 2020-06-29 2021-10-19 金电联行（北京）信息技术有限公司 一种使用多基线校正模型的传染病趋势预测方法与系统
US20230310569A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
EP4048308A1 (en) 2020-12-23 2022-08-31 Infectious Disease Research Institute Solanesol vaccine adjuvants and methods of preparing same
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
CA2030212A1 (en) * 1989-11-22 1991-05-23 Judson V. Edwards Peptides
US6136781A (en) * 1995-04-28 2000-10-24 Takeda Chemical Industries, Ltd. LH-RH receptor antagonists
BR9708082A (pt) * 1996-03-15 1999-07-27 Corixa Corp Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
CN1195851C (zh) * 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
US6130043A (en) * 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
NZ509178A (en) 2004-04-30
KR20010083111A (ko) 2001-08-31
SA99200618B1 (ar) 2007-01-20
CN1315998A (zh) 2001-10-03
HUP0203035A2 (hu) 2002-12-28
AU2003248213A1 (en) 2003-10-30
JP2002520054A (ja) 2002-07-09
CN100419079C (zh) 2008-09-17
NO20010196D0 (no) 2001-01-12
PL200772B1 (pl) 2009-02-27
AU5314899A (en) 2000-02-07
EP1097208A2 (en) 2001-05-09
WO2000004149A2 (en) 2000-01-27
CZ2001149A3 (cs) 2002-02-13
HUP0203035A3 (en) 2007-12-28
IL140845A0 (en) 2002-02-10
KR20070112860A (ko) 2007-11-27
BR9912007A (pt) 2002-01-29
TW200728465A (en) 2007-08-01
EP1870466A3 (en) 2008-03-19
AU762812B2 (en) 2003-07-03
EP1870466A2 (en) 2007-12-26
WO2000004149A3 (en) 2000-07-20
TW200532020A (en) 2005-10-01
PL346359A1 (en) 2002-02-11
TR200100916T2 (no) 2002-06-21
CA2334038A1 (en) 2000-01-27

Similar Documents

Publication Publication Date Title
NO20010196L (no) Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft
NO20023402D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft
NO20016427L (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
NO20003853L (no) Forbindelser for terapi og diagnose av lungekreft og metoder for deres anvendelse
NO20013002D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1515982A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
NO20014769L (no) Preparat for behandling og diagnostikk av brystcancer og fremgangsmater for anvendelse derav
DK0972201T3 (da) Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
PL366626A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
NO994932D0 (no) Blandinger og fremgangsmaater for behandling og diagnose av brystkreft
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001250932A8 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
NO20014804L (no) Forbindelser for immunterapi og diagnose av brystkreft og fremgangsmåter for deres anvendelse
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
PL366066A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka sutka

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application